Micropulse Laser versus Eplerenone for Chronic Central Serous Chorioretinopathy: A 12-Month Comparison.
Central serous chorioretinopathy
OCT
Optical coherence tomography
Pachychoroid
Subfoveal choroidal thickness
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
12
09
2024
accepted:
10
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
aheadofprint
Résumé
To compare the long-term efficacy of navigated subthreshold micropulse laser (NSML) and continuous oral eplerenone (EPL) in chronic central serous chorioretinopathy (cCSC). This retrospective observational study included 44 eyes with cCSC (EPL: n = 26; NSML: n = 18). Best-corrected visual acuity (BCVA), central macular thickness (CMT), subretinal fluid (SRF) height, and subfoveal choroidal thickness (SFCT) were evaluated over 12 months. Both groups showed significant improvements in BCVA and CMT (p < 0.05). Complete SRF resolution was achieved in both groups by 12 months, with NSML showing faster resolution (2.77 ± 1.43 vs. 6.34 ± 2.17 months, p < 0.001). The EPL group demonstrated significant SFCT reduction at 6 and 12 months (p = 0.001), while the NSML group showed no significant SFCT changes (p > 0.05). Both NSML and EPL improved retinal morphology and visual function in patients with cCSC. NSML achieved faster SRF resolution, while EPL resulted in more significant choroidal thickness reduction. These findings suggest distinct mechanisms of action: NSML primarily affects the retinal pigment epithelium, while EPL modulates choroidal vasculature. Treatment choice may depend on individual patient characteristics and treatment goals.
Identifiants
pubmed: 39460897
doi: 10.1007/s40123-024-01059-x
pii: 10.1007/s40123-024-01059-x
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.
doi: 10.1016/j.ophtha.2007.02.032
pubmed: 18166410
Van RTJ, Van DEHC, Yzer S, Ohno-matsui K, Keunen JEE, Schlingemann RO, et al. Progress in retinal and eye research central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73: 100770.
doi: 10.1016/j.preteyeres.2019.07.003
Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol. 2013;41:201–14.
doi: 10.1111/j.1442-9071.2012.02848.x
pubmed: 22788735
Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina. 2016;36:499–516.
doi: 10.1097/IAE.0000000000000742
pubmed: 26335436
Loo RH, Scott IU, Flynn HW, Gass JDM, Murray TG, Lewis M, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19–24.
doi: 10.1097/00006982-200202000-00004
pubmed: 11884873
Fok ACT, Chan PPM, Lam DSC, Lai TYY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46:160–3.
doi: 10.1159/000324599
pubmed: 21389741
Chhablani J, Cohen FB, Aymard P, Beydoun T, Bousquet E, Daruich-Matet A, et al. Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retina. 2020;4:1043–6.
doi: 10.1016/j.oret.2020.07.026
pubmed: 33131671
Canakis C, Livir-Rallatos C, Panayiotis Z, Livir-Rallatos G, Persidis E, Conway MD, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136:750–2.
doi: 10.1016/S0002-9394(03)00397-0
pubmed: 14516825
Koh AHC. Photodynamic therapy for focal RPE leaks. Ophthalmology. 2006;113:2110.e1-2110.e3.
doi: 10.1016/j.ophtha.2006.06.008
pubmed: 17074572
Demirel S, Özcan G, Yanık Ö, Batıoğlu F, Özmert E. Vascular and structural alterations of the choroid evaluated by optical coherence tomography angiography and optical coherence tomography after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:905–12.
doi: 10.1007/s00417-018-04226-6
Karasu B, Akbas YB, Aykut A, Celebi ARC. Comparison of retinochoroidal vascular and structural changes after half-dose photodynamic therapy versus half-fluence photodynamic therapy based on optical coherence tomography angiography in eyes with chronic central serous chorioretinopathy. Ophthalmologica. 2022;245:323–34.
doi: 10.1159/000523704
pubmed: 35249031
Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Mizota A, et al. Quantification of metamorphopsia in chronic central serous chorioretinopathy after half-dose verteporfin photodynamic therapy. Retina. 2014;34:964–70.
doi: 10.1097/IAE.0000000000000027
pubmed: 24406387
Toto L, Ruggeri ML, Evangelista F, Viggiano P, D’Aloisio R, De Nicola C, et al. Choroidal modifications assessed by means of choroidal vascularity index after oral eplerenone treatment in chronic central serous chorioretinopathy. Eye (Lond). 2022;2:8.
Iacono P, Toto L, Costanzo E, Varano M, Parravano MC. Pharmacotherapy of central serous chorioretinopathy: a review of the current treatments. Curr Pharm Des. 2018;24:4864–73.
doi: 10.2174/1381612825666190123165914
pubmed: 30674250
Viggiano P, Boscia G, Borrelli E, Toto L, Grassi MO, Evangelista F, et al. Choriocapillaris reperfusion in resolved chronic central serous chorioretinopathy treated with eplerenone: long-term effects on the fellow eye. Ophthalmol Ther [Internet]. 2023 [cited 2024 Jul 21];12:3199–210. Available from: https://pubmed.ncbi.nlm.nih.gov/37747638/
Borselli M, Rossi C, Chisari D, Carnovale Scalzo G, Lucisano A, Randazzo G, et al. Current and emerging treatment options for central serous chorioretinopathy. Expert Rev Ophthalmol. 2024;19:247–60.
doi: 10.1080/17469899.2024.2336241
Sacconi R, Borrelli E, Querques G. Eplerenone for chronic central serous chorioretinopathy. Lancet. England; 2020. p. 1556.
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Ellis L, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294–303.
doi: 10.1016/S0140-6736(19)32981-2
pubmed: 31982075
Lotery A, Sivaprasad S, O’Connell A, Harris RA, Culliford L, Cree A, et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT. Effic Mech Eval. 2021;8:1–82.
doi: 10.3310/eme08020
Kim YJ, Kim SY, Ha S, Moon D, Seong S, Kwon OW, et al. Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years. Eye (Lond). 2019;33:819–25.
doi: 10.1038/s41433-018-0309-7
pubmed: 30610228
Inagaki K, Shuo T, Katakura K, Ebihara N, Murakami A, Ohkoshi K. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells. J Ophthalmol. 2015;2015: 729792.
pubmed: 26697211
pmcid: 4677213
Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274–84.
doi: 10.2174/157339912800840523
pubmed: 22587512
pmcid: 3412206
Toto L, D’Aloisio R, De Nicola C, Evangelista F, Ruggeri ML, Cerino L, et al. Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy. Sci Rep. 2022;12:4727.
doi: 10.1038/s41598-022-08764-2
pubmed: 35304566
pmcid: 8933552
Vignesh TP, Maitray A, Sen S, Chakrabarti A, Kannan NB, Ramasamy K. Subthreshold micro-pulse yellow laser and eplerenone drug therapy in chronic central serous chorio-retinopathy patients: a comparative study. Semin Ophthalmol. 2020;35:237–45.
doi: 10.1080/08820538.2020.1809682
pubmed: 32853034
Viggiano P, Miere A, Borrelli E, Boscia G, Grassi MO, Souied EH, et al. The impact of diabetic retinopathy on the choriocapillaris in neovascular AMD. Invest Ophthalmol Vis Sci [Internet]. 2023 [cited 2024 May 27];64. Available from: https://pubmed.ncbi.nlm.nih.gov/37988106/
Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D. Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol. 1994;112:1057–62.
doi: 10.1001/archopht.1994.01090200063023
pubmed: 8053819
Viggiano P, Grassi MO, Boscia G, Pignataro M, Petruzzella G, Borrelli E, et al. Short-term morphofunctional changes in previously treated neovascular AMD eyes switched to brolucizumab. J Clin Med. 2022;11:8.
doi: 10.3390/jcm11195517
Viggiano P, Vujosevic S, Palumbo F, Grassi MO, Boscia G, Borrelli E, et al. Optical coherence tomography biomarkers indicating visual enhancement in diabetic macular edema resolved through anti-VEGF therapy: OCT biomarkers in resolved DME. Photodiagnosis Photodyn Ther [Internet]. 2024 [cited 2024 May 27];46. Available from: https://pubmed.ncbi.nlm.nih.gov/38460657/
Borrelli E, Costanzo E, Parravano M, Viggiano P, Varano M, Giorno P, et al. Impact of bleaching on photoreceptors in different intermediate AMD phenotypes. Transl Vis Sci Technol. 2019;8:5–5.
doi: 10.1167/tvst.8.6.5
pubmed: 31737429
pmcid: 6855373
Viggiano P, Bisceglia G, Bacherini D, Chhablani J, Grassi MO, Boscia G, et al. Long-term visual outcomes and optical coherence tomography biomarkers in eyes with macular edema secondary to retinal vein occlusion following anti-vascular endothelial growth factor therapy. Retina. 2024;44:1572–9.
doi: 10.1097/IAE.0000000000004157
pubmed: 39087483
Boscia G, Viggiano P, Marzulli F, Grassi MO, Puzo P, Dore S, et al. Continuous eplerenone treatment in chronic central serous chorioretinopathy: long-term results from a pilot study. Clin Ophthalmol. 2023;17:2003–12.
doi: 10.2147/OPTH.S411094
pubmed: 37483844
pmcid: 10361091
Koytak A, Erol K, Coskun E, Asik N, Öztürk H, Özertürk Y. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30:1698–703.
doi: 10.1097/IAE.0b013e3181da4354
pubmed: 20539254
Xu Y, Su Y, Li L, Qi H, Zheng H, Chen C. Effect of photodynamic therapy on optical coherence tomography angiography in eyes with chronic central serous chorioretinopathy. Ophthalmologica. 2017;237:167–72.
doi: 10.1159/000456676
pubmed: 28171871
Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, et al. Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. Am J Ophthalmol. 2020;217:104–13.
doi: 10.1016/j.ajo.2020.04.022
pubmed: 32360342
Wood EH, Karth PA, Sanislo SR, Moshfeghi DM, Palanker DV. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence? Retina. 2017;37:1021–33.
doi: 10.1097/IAE.0000000000001386
pubmed: 27841848
Li X, Long H, Hu Q. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: a meta-analysis. Photodiagnosis Photodyn Ther. 2022;39: 102931.
doi: 10.1016/j.pdpdt.2022.102931
pubmed: 35636735
Scholz P, Ersoy L, Boon CJF, Fauser S. Subthreshold micropulse laser (577 nm) treatment in chronic central serous chorioretinopathy. Ophthalmologica. 2015;234:189–94.
doi: 10.1159/000439600
pubmed: 26406874
Sun Z, Huang Y, Nie C, Wang Z, Pei J, Lin B, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy. Eye (Lond). 2020;34:1592–9.
doi: 10.1038/s41433-019-0692-8
pubmed: 31784704
Luttrull JK. Low-intensity/high-density subthreshold diode micropulse laser for central serous chorioretinopathy. Retina. 2016;36:1658–63.
doi: 10.1097/IAE.0000000000001005
pubmed: 27206160
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2013;33:2096–102.
doi: 10.1097/IAE.0b013e318297a07a
pubmed: 23719402
Gergely R, Kovács I, Schneider M, Resch M, Papp A, Récsán Z, et al. Mineralocorticoid receptor antagonist treatment in bilateral chronic central serous chorioretinopathy: a comparative study of exudative and nonexudative fellow eyes. Retina. 2017;37:1084–91.
doi: 10.1097/IAE.0000000000001303
pubmed: 27627749
Rajesh B, Agrawal H, Peguda HK, Chhablani J. Predictors of outcome during eplerenone therapy in chronic central serous chorioretinopathy: a prospective, open-label pilot clinical study. Ophthalmic Surg Lasers Imaging Retina. 2018;49:479–86.
doi: 10.3928/23258160-20180628-03
pubmed: 30021034
Dupont JJ, Hill MA, Bender SB, Jaisser F, Jaffe IZ. Aldosterone and vascular mineralocorticoid receptors: regulators of ion channels beyond the kidney. Hypertension. 2014;63:632.
doi: 10.1161/HYPERTENSIONAHA.113.01273
pubmed: 24379184